Description

Lirilumab is a fully human monoclonal antibody designed as a checkpoint inhibitor targeting the killer-cell immunoglobulin-like receptor (KIR). This compound is of significant interest in the field of immuno-oncology for its potential to enhance natural killer (NK) cell-mediated antitumor activity. It is primarily utilized in advanced pharmaceutical research and development for novel cancer immunotherapies. Global suppliers and research institutions require this high-purity biological agent for preclinical studies and clinical trial material production.

Application

• Immuno-oncology Research: A key reagent for studying NK cell function and immune checkpoint pathways in cancer models.
• Therapeutic Antibody Development: Serves as a reference standard or active pharmaceutical ingredient (API) in the development of KIR-targeting immunotherapies.
• Preclinical Studies: Used in in vitro and in vivo experiments to evaluate efficacy, pharmacokinetics, and mechanism of action.
• Clinical Trial Material: Sourced for the GMP-compliant manufacture of drug product for Phase I-III clinical trials in oncology.
• Biomarker Discovery: Employed in assays to identify patient populations likely to respond to KIR blockade therapy.
• Combination Therapy Research: Investigated in conjunction with other immunomodulators, chemotherapy, or radiotherapy to enhance therapeutic outcomes.

Basic Information

Product Name	Lirilumab
CAS No.	1000676-41-4
Molecular Formula	Data on request
Molecular Weight	Approx. 145 kDa
Synonyms	Anti-KIR Antibody; IPH2101; BMS-986015; Anti-KIR2DL1/KIR2DL2/KIR2DL3 Antibody; Monoclonal Antibody to KIR; 1-7F9; KIR Inhibitor IPH2101
EINECS	Contact for details

Quality Control

Our Lirilumab is produced and tested under stringent quality systems to ensure it meets the exacting standards required for research and pharmaceutical development. Each batch is characterized for identity, purity, potency, and stability. Comprehensive analysis includes SDS-PAGE, SEC-HPLC for monomeric purity, endotoxin testing, and functional bioassays. A Certificate of Analysis (COA) detailing all specifications and test results is provided with every shipment.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store at -20°C to -80°C. Avoid repeated freeze-thaw cycles. The product is hygroscopic (moisture-sensitive); ensure containers are sealed under controlled humidity conditions or with desiccant when applicable.

Specification

Item	Specification
Appearance	Clear to slightly opalescent, colorless to pale yellow solution
Identification (SDS-PAGE)	Consistent with reference standard
Purity (SEC-HPLC)	≥95% Monomer
Protein Concentration	As per COA (typically 1-10 mg/mL)
Endotoxin	<1.0 EU/mg
Potency (Cell-based Assay)	EC50 within defined range
Buffer	Specified formulation (e.g., PBS, Histidine buffer)

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.